Estrogen receptor α and β competitor assay kits

Melting points were determined using capillary tubes with a Mel-Temp apparatus and are uncorrected. The nuclear magnetic resonance (¹H and ¹³C NMR) spectra were recorded using a Bruker ARX300 spectrometer (300 MHz) with a QNP probe or a Bruker DRX-2 spectrometer (500 MHz) with a BBO probe. High-resolution mass spectra were recorded on a double-focusing sector mass spectrometer with magnetic and electrostatic mass analyzers. The purities of biologically important compounds are determined by HPLC or elemental analyses. For elemental analyses, the observed percentages differ less than 0.40% from the calculated values. For HPLC, the major peak accounted for ≥95% of the combined total peak area when monitored by a UV detector at 254 nm. The HPLC analyses were performed on a Waters 1525 binary HPLC pump/Waters 2487 dual λ absorbance detector system using a 5 μm C18 reversed phase column. The cytochrome P450 (CYP) inhibitor screening kit for aromatase (CYP19) was purchased from BD Biosciences (San Jose, CA). Estrogen receptor α and β competitor assay kits were purchased from Invitrogen (Carlsbad, CA).

Melting points were determined using capillary tubes with a Mel-Temp apparatus and are uncorrected. The nuclear magnetic resonance (¹H and ¹³C NMR) spectra were recorded using a Bruker ARX300 spectrometer (300 MHz) with a QNP probe or a Bruker DRX-2 spectrometer (500 MHz) with a BBO probe. High-resolution mass spectra were recorded on a double-focusing sector mass spectrometer with magnetic and electrostatic mass analyzers. The purities of biologically tested compounds are ≥ 95% as determined by HPLC or elemental analyses. For elemental analyses, the observed percentages differ less than 0.40% from the calculated values. For purities estimated by HPLC, the major peak accounted for ≥ 95% of the combined total peak area when monitored by a UV detector at 254 nm. The HPLC analyses were performed on a Waters 1525 binary HPLC pump/Waters 2487 dual λ absorbance detector system using a 5 μm C18 reversed phase column. Cytochrome P450 (CYP) inhibitor screening kits for aromatase (CYP19) inhibition studies were purchased from BD Biosciences (San Jose, CA). Estrogen receptor α and β competitor assay kits were purchased from Invitrogen (Carlsbad, CA).